Menovag

Estradiol, the active ingredient in Menovag, is an estrogen presented as an unspecified strength vaginal tablet for vaginal use. It restores local estrogen levels in the vaginal epithelium, helping to alleviate symptoms associated with estrogen deficiency such as dryness, irritation, and discomfort in post‑menopausal women.

GNH USA supplies Menovag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets.

Menovag (estradiol) is used in estrogen‑dependent conditions of the female genital tract, primarily to address menopausal changes.

Vaginal atrophy: improves epithelial thickness and lubrication, reducing dryness and discomfort. Genitourinary syndrome of menopause: alleviates dyspareunia, itching and urinary symptoms linked to estrogen loss. Estrogen deficiency after oophorectomy: restores local estrogen activity to support vaginal health.

Estradiol administered vaginally can be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Vaginal irritation or burning: mild discomfort at the application site. - Increased vaginal discharge: watery or milky secretion. - Breast tenderness: mild swelling or soreness. - Headache: transient mild headache.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Endometrial hyperplasia or carcinoma: abnormal uterine bleeding. - Severe allergic reaction: rash, swelling, or anaphylaxis.

When prescribing Menovag, clinicians should consider several safety precautions to minimize risk.

Contraindications: known history of thromboembolic disease or estrogen‑dependent neoplasia. Bleeding assessment: monitor for abnormal vaginal bleeding or spotting. Liver function: evaluate hepatic impairment before use. Cardiovascular risk: assess hypertension, smoking status, and age. Pregnancy and lactation: avoid unless clearly indicated by a physician. Store at room temperature: keep in original packaging, protect from moisture and light.

Estradiol can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Combined hormonal contraceptives: additive estrogen effect increasing thrombotic risk. - Anticoagulants (warfarin, DOACs): potential for enhanced clotting complications. - Selective estrogen receptor modulators (tamoxifen, raloxifene): antagonistic actions reducing therapeutic benefit.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (ketoconazole, itraconazole): may raise estradiol plasma levels. - Antihypertensives (ACE inhibitors, beta‑blockers): possible fluid retention exacerbation. - Lithium: may affect hormone metabolism and require monitoring.